Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIFAstrat: Optimised Rifampicin for TB
NCT07118696Phase 3Not yet recruiting
- Sponsor
- Hamilton Health Sciences
- Start
- Feb 2026
- Primary completion
- Jan 2029
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of rifampicin in pulmonary tuberculosis (TB), sponsored by Hamilton Health Sciences. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
rifampicin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT07118696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07118696.